Boundless Bio reprices options for execs to $3.56; CEO Hornby holds 1.15M repriced options

Boundless Bio, Inc.

Exercise price reduced to $3.56 (Aug 19, 2024 close) for options originally priced at or above $3.71.
Repriced options may only be exercised at the lower price if held through the Premium End Date (Aug 19, 2026, or earlier change in control or qualifying termination).
CEO Zachary D. Hornby: 1,147,242 options repriced (original exercise range $4.10–$16.00).
CMO Klaus Wagner: 316,893 options; CSO Chris Hassig: 292,821 options repriced.
Repricing intended to retain key employees without incurring dilution from additional equity grants or cash compensation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.